Law360: Economics Of Harm From Biologic-Biosimilar Competition
For more than two decades and despite the Biologics Price Competition and Innovation Act of 2009, the Hatch-Waxman brand-generic disputes have dominated the...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Product development in the life sciences sector is frequently complex, costly, and time-consuming, and collaborations between companies are common. Disputes may arise at all stages of development and commercialization. Our experience helps clients navigate disputes involving drug development and commercialization and identify relevant commercial factors (size of the opportunity, therapeutic area, business risks, etc.). CRA has provided expert reports and testimony evaluating development and commercialization efforts and assessing damages associated with alleged contractual breaches.